留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

关注胃肠道黏膜屏障,规范黏膜保护剂应用——《胃肠道黏膜保护临床专家共识(2021年,福州)》解读

李景南

李景南. 关注胃肠道黏膜屏障,规范黏膜保护剂应用——《胃肠道黏膜保护临床专家共识(2021年,福州)》解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0256
引用本文: 李景南. 关注胃肠道黏膜屏障,规范黏膜保护剂应用——《胃肠道黏膜保护临床专家共识(2021年,福州)》解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0256
LI Jingnan. Focus on the Gastrointestinal Mucosal Barrier and Standardize the Application of Mucosal Protective Agents: Interpretation on the Consensus of Clinical Experts on Gastrointestinal Mucosal Protection(2021, Fuzhou)[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0256
Citation: LI Jingnan. Focus on the Gastrointestinal Mucosal Barrier and Standardize the Application of Mucosal Protective Agents: Interpretation on the Consensus of Clinical Experts on Gastrointestinal Mucosal Protection(2021, Fuzhou)[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0256

关注胃肠道黏膜屏障,规范黏膜保护剂应用——《胃肠道黏膜保护临床专家共识(2021年,福州)》解读

doi: 10.12290/xhyxzz.2022-0256
详细信息
    通讯作者:

    李景南,E-mail:lijn2008@126.com

  • 中图分类号: R816.5;R975

Focus on the Gastrointestinal Mucosal Barrier and Standardize the Application of Mucosal Protective Agents: Interpretation on the Consensus of Clinical Experts on Gastrointestinal Mucosal Protection(2021, Fuzhou)

  • 摘要: 胃肠道是人体与外界相通的最大器官,其黏膜不仅是机体与外界联系的重要屏障,也是胃肠道各种功能得以正常维持的基础。胃肠道黏膜屏障功能是胃肠道疾病发生发展的共同病理生理基础。目前,针对胃肠道黏膜,尤其是小肠黏膜仍缺乏深入系统的认识,临床实践中更多关注损伤因子的作用,忽略了黏膜防护的重要性。为提高医务人员对胃肠道黏膜保护的认识,规范黏膜保护剂的应用,中华医学会消化病分会胃肠激素与黏膜屏障学组制定了我国第一部胃肠道黏膜保护专家共识,于2021年底正式发布。本文针对共识制定的背景、过程和主要内容进行解读,以帮助医务人员提高认识,规范临床诊疗。
  • [1] Camilleri M. Leaky gut:mechanisms, measurement and clinical implications in humans[J]. Gut, 2019, 68:1516-1526.
    [2] 中华医学会消化病学分会胃肠激素与黏膜屏障学组.胃肠道黏膜保护临床专家共识(2021年,福州)[J].中华消化杂志, 2021, 41:798-811. Gastrointestinal Hormone and Mucosal Barrier Group, Chinese Society of Gastroenterology, Chinese Medical Association.Consensus of clinical experts on gastrointestinal mucosal protection (2021

    , Fuzhou)[J].Zhonghua Xiaohua Zazhi, 2021, 41:798-811.
    [3] Yandrapu H, Sarosiek J. Protective Factors of the Gastric and Duodenal Mucosa:An Overview[J]. Curr Gastroenterol Rep, 2015, 17:24.
    [4] Capaldo CT, Powell DN, Kalman D. Layered defense:how mucus and tight junctions seal the intestinal barrier[J]. J Mol Med (Berl), 2017, 95:927-934.
    [5] Paone P, Cani PD. Mucus barrier, mucins and gut microbiota:the expected slimy partners?[J]. Gut, 2020, 69:2232-2243.
    [6] Allam-Ndoul B, Castonguay-Paradis S, Veilleux A. Gut Microbiota and Intestinal TransEpithelial Permeability[J]. Int J Mol Sci, 2020, 21:6402
    [7] Wirth HP, Yang M. Different Pathophysiology of Gastritis in East and West? A Western Perspective[J]. Inflamm Intest Dis, 2016, 1:113-122.
    [8] Guzmán-Mejía F, Godínez-Victoria M, Vega-Baurista A, et al. Intestinal Homeostasis under Stress Siege[J]. Int J Mol Sci, 2021, 22:5095
    [9] 杨莹韵,李渊,张海芳,等.北京地区慢性非萎缩性胃炎伴糜烂患者277例的病因及治疗现状[J].中华消化杂志, 2021, 41:27-32. Yang YY, Li Y, Zhang HF, et al.Etiology and current treatment status of 277

    patients with chronic atrophic gastritis and erosion in Beijing area[J]. Zhonghua Xiaohua Zazhi, 2021, 41:27-32.
    [10] Watanabe T, Fujiwara Y, Chan FKL. Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage:a comprehensive review[J]. J Gastroenterol, 2020, 55:481-495.
    [11] Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis[J]. Cancer, 2003, 98:1531-1539.
    [12] Chulkina M, Beswick EJ, Pinchuk IV. Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation[J]. Int J Mol Sci, 2020, 21:9165
    [13] Gyires K, Laszlo SB, Lazar B, et al. Similar and Distinct Mechanisms in the Protective Processes of Upper and Lower Gastrointestinal Tract[J]. Curr Pharm Des, 2018, 24:1936-1946.
    [14] Xiong L, Huang X, Li L, et al. Geranylgeranylacetone protects against small-intestinal injuries induced by diclofenac in patients with rheumatic diseases:a prospective randomized study[J]. Dig Liver Dis, 2015, 47:280-284.
    [15] Kuramoto T, Umegaki E, Nouda S, et al. Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study[J]. BMC Gastroenterol, 2013, 13:85.
    [16] 韩涛涛,陈楚岩,王静,等.瑞巴派特对非甾体抗炎药相关小肠黏膜损伤的保护机制[J].中华消化杂志, 2021, 41:183-189. Han TT, Chen CY, Wang J, et al.Protective mechanism of rebamipide on non-steroid antiinflammatory drug related small intestinal mucosal injury[J]. Zhonghua Xiaohua Zazhi, 2021

    , 41:183-189.
  • 加载中
计量
  • 文章访问数:  5
  • HTML全文浏览量:  0
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-06
  • 网络出版日期:  2022-06-11

目录

    /

    返回文章
    返回

    尊敬的审稿专家、作者及读者朋友,因特殊原因,网站于6月30日24时至7月1日24时为镜像,在此期间登录及上传和更新功能将受到影响,给您带来不便,敬请谅解。